PLK4 and thyroid gland undifferentiated (anaplastic) carcinoma: PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer